Canada Markets open in 39 mins

Soligenix, Inc. (SNGX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8001-0.0399 (-4.75%)
At close: 04:00PM EDT
0.8299 +0.03 (+3.72%)
Pre-Market: 08:00AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8400
Bid0.0000 x 1200
Ask0.0000 x 1200
Day's Range0.7900 - 0.8500
52 Week Range0.3800 - 1.2300
Avg. Volume219,235
Market Cap34.303M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.3630
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.88
  • GlobeNewswire

    Presenting on the Emerging Growth Conference on August 17 Register Now

    Niche Companies in, Technology, Real Estate, Food & Beverage, Biotechnology, Precious Metals, Cyber Security and more in attendanceMIAMI, Aug. 16, 2022 (GLOBE NEWSWIRE) -- a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 37th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with str

  • Newsfile

    Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients

    HyBryte(TM) NDA Anticipated in H2 2022 New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX), has completed the largest placebo controlled, randomized Phase 3 trial ever done in cutaneous T-cell lymphoma (CTCL) evaluating a novel topical treatment for early-stage CTCL and is preparing to submit a New Drug Application to the FDA to commercialize the product.Soligenix, Inc.To view an enhanced version of this graph

  • Newsfile

    Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis

    Strategy supports global need and has potential use in growing home healthcare market New York, New York--(Newsfile Corp. - June 7, 2022) - PCG Digital -- Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and commercializing products to treat rare diseases where there is an unmet medical need. (Rising to the challenges of rare disease treatment)To view an enhanced version of this graphic, please visit:https://orders.n